Secondary hormonal manipulations in the treatment of castration refractory prostate cancer

K E T O C O N A Z O L E I N A D V A N C E D P R O S T A T E C A N C E R 2006, Edinburgh, Scotland: National 13 Taplin ME, Regan MM, Ko YJ et al.
Cancer Institute, 2009. Available at: http:/ 22 Galsky MD, Simon K, Sonpavde G et al.
Ketoconazole retains activity in patients Ferlay J, Parkin DM, Steliarova-Foucher
prostate cancer. Clin Cancer Res 2009; cancer. Ann Oncol 2009; 20: 965-6
E. Estimates of cancer incidence and
15: 7099-105
23 Scholz M, Jennrich R, Strum S,
mortality in Europe in 2008. Eur J Cancer 14 Wilkinson S, Chodak G. An evaluation
Brosman S, Johnson H, Lam R. Long-
2010; 46: 765-81
Touijer K, Scardino PT. Nomograms for
hormone refractory prostate cancer. Eur independent prostate cancer treated with Urol 2004; 45: 581-4
ketoconazole and hydrocortisone. J Urol treatment outcomes. Cancer 2009; 115
15 Simon R. Optional two-stage designs for
2005; 173: 1947-52
phase II clinical trials. Control Clin Trials 24 Nakabayashi M, Xie W, Regan MM,
Miyamoto H, Messing EM, Chang C.
1989; 10: 1-10
Jackman DM, Kantoff PW, Oh WK.
16 Armstrong AJ, Garrett-Mayer ES,
prostate cancer: current status and future Yang YC, de Wit R, Tannock IF,
prospects. Prostate 2004; 61: 332-53
Eisenberger M. A contemporary
Lam JS, Leppert JT, Vemulapalli SN,
independent prostate cancer. Cancer Shvarts O, Belldegrun AS. Secondary
2006; 107: 975-81
25 Nakabayashi M, Oh WK, Jacobus S et al.
cancer. J Urol 2006; 175: 27-34
analysis. Clin Cancer Res 2007; 13:
Chaudhary UB, Rashid MH, Onitilo
AA, Bissada NK. Secondary hormonal
17 Sternberg CN, Petrylak DP, Sartor O
resistant prostate cancer. BJU Int 2010; et al. Multinational, double-blind, phase III
105: 1353-484
advanced prostate cancer. Can J Urol study of prednisone and either satraplatin 2005; 12: 2666-76
Berthold DR, Pond GR, Soban F, de Wit
Fondazione Istituto Nazionale Tumori, Via G. R, Eisenberger M, Tannock IF. Docetaxel
after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8
e-mail: giuseppe.procopio@istitutotumori.
prednisone for advanced prostate cancer: 18 Loriot Y, Massard C, Gross-Goupil M
et al. Combining carboplatin and
J Clin Oncol 2008; 26: 242-5
Abbreviations: CRPC, castration-resistant
Petrylak DP, Tangen CM, Hussain
prostate cancer; CR + PR + SD, complete
HM et al. Docetaxel and extramustine
response + partial response + stable disease.
evaluating also neuroendocrine features. Ann Oncol 2009; 20: 703-8
prostate cancer. N Engl J Med 2004; 351:
19 Danila DC, Morris MJ, de Bono JS et al.
Phase 2 multicenter study of abiraterone EDITORIAL COMMENT
Tannock IF, de Wit R, Berry WR et al.
patients with docetaxel treated castration SECONDARY HORMONAL
resistano prostate cancer. J Clin Oncol MANIPULATIONS IN THE TREATMENT OF
prednisone for advanced prostate cancer. 2010; 28: 1496-501
CASTRATION REFRACTORY PROSTATE
N Engl J Med 2004; 351: 1502-12
20 Sartor AO, Oudard S, Ozguroglu M
10 Pienta KJ, Bradley D. Mechanisms
et al. Cabazitaxel or mitoxantrone with
The cornerstone of treatment for advanced independent prostate cancer. Clin Cancer Res 2006; 15: 1665-71
castration i.e. androgen deprivation therapy 11 Madan RA, Lieberman R, Gulley J,
docetaxel: final results of a multinational (ADT). Despite initial responses, almost all Dahut W, Arlen PM. Significant
phase 3 trial. Proceedings of the American prostate-specific antigen (PSA) response prostate cancer (CRPC). In CRPC, most tumors remain dependent on androgen receptor (AR) Francisco. Pro ASCO GU 2010 abstract no. signaling for proliferation [1] and many CRPC independent prostate cancer (AIPC) and a review of the literature. Am J Ther 2007; 21 Kantoff P, Higano CS, Berger ER et al.
14: 310-13
12 Reid AH, Attard G, Barrie E, de Bono JS.
In this paper, Procopio et al. report on the for prostate cancer. Nat Clin Pract Urol efficacy of low dose ketoconazole (200 mg 2008; 5: 610-20
orally every eight hours) in a phase 2, single 2 0 1 0 T H E A U T H O R SB J U I N T E R N A T I O N A L 2 0 1 0 B J U I N T E R N A T I O N A L Higher baseline androstenedione levels were Small EJ, Vogelzang NJ. Second-line
primary endpoint was PSA response, which was defined as partial response (PR) i.e. cancer: a shifting paradigm. J Clin Oncol PSA ≤50% or complete response (CR) i.e. ketoconazole (200 mg orally thrice daily) has 1997; 15: 382-8
undetectable PSA. There were two CRs and 6 also been shown to be associated with PSA Nakabayashi M, Oh WK, Jacobus S et al.
PRs, with an overall PSA response rate of 21%. These included one CR and four PRs in 15 patients with prior chemotherapy. However resistant prostate cancer. BJU Int 2010; the median duration of benefit was only 21 105: 1392-6
weeks (5 months) similar to prior reports of Scher HI, Halabi S, Tannock I et al.
Design and end points of clinical trials for signaling in disease progression in CRPC has patients with progressive prostate cancer It is of interest that 31 of 37 patients had led to the development of newer drugs such as abiraterone and MDV 3100. Abiraterone acetate (Johnson & Johnson, New Brunswick, Clinical Trials Working Group. J Clin Oncol NJ), is an orally administered pregnenolone 2008; 26: 1148-59
meaning with respect to response, and has analog that irreversibly inhibits CYP17 (a key Chen Y, Clegg NJ, Scher HI. Anti-
been misconstrued as suggestive of clinical enzyme in androgen synthesis) and blocks the benefit [4]. Therefore, the Prostate Cancer synthesis of androgens in the testes, adrenal Clinical Trials Working Group 2 (PCWG2) has glands and prostate, without causing adrenal insufficiency [1]. MDV 3100 (Medivation Inc, The Lancet Oncology 2009; 10:
San Francisco, CA) is an orally administered maximal PSA decline/patient be reported in a novel AR antagonist that binds to AR with a Small EJ, Halabi S, Dawson NA et al.
waterfall plot. Waterfall plots allow a given much higher affinity (eight times higher) than data set to be analyzed on the basis of any bicalutamide and blocks nuclear translocation degree of decline and to be compared to other promising results of phase 2 clinical trials, patients: a phase III trial (CALGB 9583). there are currently several ongoing phase 3 J Clin Oncol 2004; 22: 1025-33
Ketoconazole has a weak and non-specific Nakabayashi M, Xie W, Regan MM,
inhibitory affect on several enzymes involved patients with progressive CRPC, with results Jackman DM, Kantoff PW, Oh WK.
in androgen synthesis and has been widely expected in near future. Until more promising used in combination with hydrocortisone for ketoconazole remains a pertinent option in ketoconazole is associated with significant patients with CRPC when clinical trials are not independent prostate cancer. Cancer toxicities. The effect of ketoconazole on 2006; 107: 975-81
overall survival is difficult to discern [5]. In a phase 3 study of 260 patients with CRPC, PSA REFERENCES
responses and ORs were significantly higher Neeraj Agarwal* and
Agarwal N, Hutson TE, Vogelzang NJ,
Nicholas J. Vogelzang†,
hydrocortisone and antiandrogen withdrawal Sonpavde G. Abiraterone acetate: a
*University of Utah, Salt Lake City, UT, and There was no difference in median survival †Comprehensive Cancer Centers of Nevada, (∼16 months for both arms of the study) [6]. Future Oncol 2010; 6: 665-79
B J U I N T E R N A T I O N A L 2 0 1 0 B J U I N T E R N A T I O N A L

Source: http://www.cccnevada.com/wp-content/uploads/Vogelzang-SECONDARY-HORMONAL.pdf